These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

900 related items for PubMed ID: 16339666

  • 21. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
    Gaziev D, Galimberti M, Polchi P, Angelucci E, Giardini C, Baronciani D, Andreani M, Persini B, Erer B, Sodani P, Manna M, Nicolini G, Visani G, Lucarelli G, AIEOP.
    Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
    [Abstract] [Full Text] [Related]

  • 22. Bone marrow transplantation in class 1 thalassemia patients.
    Baronciani D, Galimberti M, Lucarelli G, Polchi P, Angelucci E, Giardini C, Giorgi C, Gaziev J.
    Bone Marrow Transplant; 1993 Jan; 12 Suppl 1():56-8. PubMed ID: 8374565
    [No Abstract] [Full Text] [Related]

  • 23. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 24. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M, Evazi MR, Mousavi SA, Shamshiri AR, Tavakoli M, Ashouri A, Samiee S, Chahardovali B, Alimoghaddam K, Ghaffari SH, Ghavamzadeh A.
    Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
    [Abstract] [Full Text] [Related]

  • 25. Long-term results of survival in patients with thalassemia major treated with bone marrow transplantation.
    Di Bartolomeo P, Santarone S, Di Bartolomeo E, Olioso P, Bavaro P, Papalinetti G, Di Carlo P, Papola F, Nicolucci A, Di Nicola M, Iacone A.
    Am J Hematol; 2008 Jul; 83(7):528-30. PubMed ID: 18383328
    [Abstract] [Full Text] [Related]

  • 26. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
    Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuk F, Krüll A, Zander A, German Study-group Multiple Myeloma (DSMM).
    Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047
    [Abstract] [Full Text] [Related]

  • 27. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
    Muñoz A, Bureo E, Ortega JJ, Richard C, Olivé T, Maldonado MS, Madero L, Díaz MA.
    Haematologica; 1998 Nov; 83(11):981-4. PubMed ID: 9864916
    [Abstract] [Full Text] [Related]

  • 28. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M, Le QH, Mohty M, Prébet T, Nicolini F, Boiron JM, Esperou H, Attal M, Milpied N, Lioure B, Bordigoni P, Yakoub-Agha I, Bourhis JH, Rio B, Deconinck E, Renaud M, Chir Z, Blaise D.
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [Abstract] [Full Text] [Related]

  • 29. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
    Casper J, Wilhelm S, Steiner B, Wolff D, Grobe N, Hähling D, Hartung G, Hilgendorf I, Lück A, Junghanss C, Kahl C, Baumgart J, Pichlmeier U, Freund M.
    Dtsch Med Wochenschr; 2005 Sep 23; 130(38):2125-9. PubMed ID: 16172951
    [Abstract] [Full Text] [Related]

  • 30. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul 23; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 31. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
    Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Sacchi N, van Lint MT, Bosi A, Gruppo Italiano Trapianti Midollo Osseo (GITMO).
    Biol Blood Marrow Transplant; 2006 May 23; 12(5):560-5. PubMed ID: 16635791
    [Abstract] [Full Text] [Related]

  • 32. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, Galambrun C, Dai Q, Maire P, Jelliffe RW, Aulagner G.
    Bone Marrow Transplant; 2001 Oct 23; 28(8):743-51. PubMed ID: 11781625
    [Abstract] [Full Text] [Related]

  • 33. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
    Kiss TL, Panzarella T, Messner HA, Meharchand J, Reddy V, Schimmer AD, Lipton JH.
    Bone Marrow Transplant; 2003 Jan 23; 31(2):73-8. PubMed ID: 12621486
    [Abstract] [Full Text] [Related]

  • 34. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
    Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ.
    Biol Blood Marrow Transplant; 2006 Dec 23; 12(12):1326-34. PubMed ID: 17162215
    [Abstract] [Full Text] [Related]

  • 35. Paediatric allogeneic bone marrow transplantation for homozygous beta-thalassaemia, the Dutch experience.
    Ball LM, Lankester AC, Giordano PC, van Weel MH, Harteveld CL, Bredius RG, Smiers FJ, Egeler RM, Vossen JM.
    Bone Marrow Transplant; 2003 Jun 23; 31(12):1081-7. PubMed ID: 12796787
    [Abstract] [Full Text] [Related]

  • 36. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug 23; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 37. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
    Zaretsky Y, Rifkind J, Lockwood G, Tsang R, Kiss T, Hasegawa W, Fyles G, Tejpar I, Loach D, Minden M, Messner H, Lipton JH.
    Bone Marrow Transplant; 2007 Sep 23; 40(5):423-30. PubMed ID: 17603516
    [Abstract] [Full Text] [Related]

  • 38. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ.
    Bone Marrow Transplant; 2007 Feb 23; 39(4):193-9. PubMed ID: 17220905
    [Abstract] [Full Text] [Related]

  • 39. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
    Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, Avalos B, Pohlman B, Marcucci G, Sobecks R, Lin T, Andrèsen S, Copelan E.
    Biol Blood Marrow Transplant; 2006 Dec 23; 12(12):1343-9. PubMed ID: 17162217
    [Abstract] [Full Text] [Related]

  • 40. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A.
    Bone Marrow Transplant; 2006 Feb 23; 37(4):339-44. PubMed ID: 16415898
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.